MDxHealth (LTS:0O8G) Moat Score: 4/10 (As of Jul. 22, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0O8G MDxHealth SA LTS:0O8G
49 GF Score
Price €3.02
GF Value €15.73
! 5 Warning Signs
View Full Analysis

What is MDxHealth Moat Score?

MDxHealth LTS:0O8G 49 Moat Score is 4 as of Jul. 22, 2026. GuruFocus rates LTS:0O8G with a GF Score™ of 49/100 and a GF Value™ of €15.73. The stock has 5 warning signs investors should review. Among 215 Medical Diagnostics & Research companies, MDxHealth ranks better than 82.79% on this metric.

MDxHealth has the Moat Score of 4, which implies that the company might have Narrow Moat - Discernible but modest moat.

MDxHealth has Narrow Moat: MDxHealth has a discernible moat based on its proprietary diagnostic technologies and patents. However, it operates in a competitive market with limited brand strength and customer switching costs.

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes MDxHealth might have Narrow Moat - Discernible but modest moat.

MDxHealth  (LTS:0O8G) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

MDxHealth Moat Score Related Terms

LTS:0O8G vs AWHL, BIOQ, XWEL: Moat Score Comparison

For the Diagnostics & Research subindustry, MDxHealth's Moat Score, along with its competitors' market caps and Moat Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

MDxHealth Moat Score vs Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, MDxHealth's Moat Score distribution charts can be found below:

* The bar in red indicates where MDxHealth's Moat Score falls into.


LTS:0O8G
49GF Score
MDxHealth SA LTS:0O8G
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Moat Score →
What does a Moat Score of 4 mean?
MDxHealth (LTS:0O8G) has a Moat Score of 4 as of Jul. 22, 2026. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. According to the industry distribution chart, MDxHealth ranks #37 out of 215 companies in the Medical Diagnostics & Research industry, placing it in the top 17.2%.
Is MDxHealth's Moat Score too high?
MDxHealth's current Moat Score is 4. Based on the distribution chart, MDxHealth ranks #37 out of 215 companies in the Medical Diagnostics & Research industry, which is in the top quartile — a strong position relative to peers. Overall, MDxHealth has a GF Score™ of 49/100, reflecting its overall financial health beyond just this single metric.
How does MDxHealth's Moat Score compare to AWHL and BIOQ?
According to the Medical Diagnostics & Research industry distribution chart, MDxHealth ranks #37 out of 215 companies for Moat Score. This places MDxHealth in the top 17% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Moat Score for a Medical Diagnostics & Research company?
A good Moat Score depends on the Medical Diagnostics & Research industry context. However, Moat Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Moat Score mean?
A high Moat Score can signal that a stock is expensive relative to its fundamentals. Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more. MDxHealth's current Moat Score is 4. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MDxHealth stock overvalued right now?
MDxHealth (LTS:0O8G) has a current Moat Score of 4. The stock's GF Value™ is €15.73, compared to a current price of €3.02 — trading 80.8% below its estimated fair value. The current Moat Score is 4. MDxHealth's overall GF Score™ is 49/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Moat Score calculated?
Moat Score is calculated from a company's financial statements. For MDxHealth (LTS:0O8G), the current Moat Score is 4 as of Jul. 22, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is MDxHealth (LTS:0O8G) Overvalued in 2026?

Based on GuruFocus' analysis, MDxHealth stock appears to be undervalued. The current stock price of €3.02 is trading 80.8% below its estimated GF Value™ of €15.73.

Key valuation signals for LTS:0O8G:

  • Moat Score: 4
  • GF Value™: €15.73 vs. price of €3.02 (80.8% below fair value)
  • GF Score™: 49/100 with 5 warning signs

No single metric tells the full story. See the LTS:0O8G stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

MDxHealth Business Description

Other Exchanges MDXH:USAO6C1:Germany
Address Zone Industrielle des Hauts-Sarts, Rue d’Abhooz, 31, Cap Business Center, Herstal, Liege, BEL, 4040
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.
49GF Score

Get the complete analysis for LTS:0O8G

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€3.02
Price
€15.73
GF Value